You are here

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Phoenix, Arizona, 85013 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer's Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of probable AD according to the NINCDS-ADRDA criteria.

- Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive.

- Able to give informed consent. Patient's caregiver must consent to participate in the
study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Significant neurologic disease other than AD that may affect cognition.

- Current clinically significant systemic illness which is likely to deteriorate or
affect the subject's safety during the study.

Other exclusions apply

NCT00151333
Pfizer
Completed
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now